October 31, 2025

New method to bring growth charts to children with rare genetic conditions through DECIPHER

New method to bring growth charts to children with rare genetic conditions through DECIPHER

A new method for building growth charts for children with rare diseases is being integrated into DECIPHER to help clinicians and families understand child development

Summary

  • A new method makes it possible to build growth charts for children with rare genetic disorders.
  • Condition-specific charts reveal how growth patterns differ for children with certain rare diseases.
  • The method is being integrated into DECIPHER so that growth charts are openly available for many rare genetic conditions.

Growth charts – used to track a child’s height and weight over time – help identify when a child’s growth is within a healthy range. But for children with rare genetic conditions, these benchmarks can be misleading. Their growth may look unusual compared to the general population, leaving families and clinicians uncertain about what is typical for their condition and making it difficult to spot when a child’s growth is deviating from what would be expected in their rare condition.

Researchers have developed a new method, called LMSz, to create condition-specific charts, giving healthcare professionals and parents clearer insights into a child’s growth and development. This new method, published in the European Journal of Human Genetics (EJHG), builds on standard population growth charts but adapts them for patient groups with rare genetic conditions where only a small number of cases are available.

This method, developed in collaboration with the DECIPHER team, is being integrated into DECIPHER, a platform hosted at EMBL-EBI for the interpretation of genomic variants for rare disease. DECIPHER has led the way in displaying condition-specific growth charts for many rare paediatric disorders. This new method will improve these charts, making them more comparable to the standard growth charts used in paediatrics. This means that improved condition-specific growth charts will soon be available for many rare conditions.

Rare disease insights

Researchers at the University of Bristol, in collaboration with DECIPHER, used the LMSz method with data from nearly 600 children worldwide to create growth charts for six rare genetic conditions:

  • ANKRD11-related KBG syndrome
  • ARID1B-related Coffin-Siris Syndrome
  • ASXL3-related Bainbridge-Ropers syndrome
  • DDX3X-related intellectual developmental disorder
  • KMT2A-related Wiedemann-Steiner syndrome
  • SATB2-related Glass syndrome

This information can help healthcare professionals make more informed decisions and give families a clearer picture of what to expect as their child grows.

“Parents of children with rare genetic conditions often feel anxious when their child’s growth looks very different from other children,” said Karen Low, NIHR Clinical Research Fellow in Bristol Medical School: Population Health Sciences (PHS). “Our growth charts help show what’s typical for that specific condition, which can provide reassurance or might highlight in which children medical intervention is required, which supports better medical care.”

The integration of this method into DECIPHER will allow new growth charts to be openly available for not only these six rare diseases, but for any rare genetic condition for which enough growth measurement data is available.

Open data impact

The open sharing of these growth charts through DECIPHER will allow the benefits of condition-specific growth information to be available to the global rare disease community.

“Integrating this new method into DECIPHER is extremely powerful as it allows a growth chart to be generated for any rare genetic condition,” said Julia Foreman, DECIPHER Project Leader at EMBL-EBI. “As more rare disease growth data is shared with DECIPHER, growth charts for more conditions will be automatically generated and immediately openly shared, bringing benefits to the rare disease community worldwide.”


Source Article

This press release was originally published by EMBL News.

Our latest News

discover more
Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Professor Dr. Hanns-Peter Knaebel has been appointed Director of Medicine at the Heidelberg and Mannheim University Hospitals Network

Effective June 1, 2026, the Supervisory Board has appointed Hanns-Peter Knaebel, Chairman of the Executive Board, to serve as Chief Medical Officer. This move will ensure that the dynamic phase of medical strategy development and transformation within the group is overseen and managed centrally by the full Executive Board. Full Text in German below. Professor […]

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

HEILBRONN, Germany, May 14, 2026 – ProtaGene today announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to provide biopharmaceutical customers with an end-to-end testing solution across the entire biopharmaceutical product lifecycle, from early-stage development through GMP release testing. ProtaGene’s expertise in advanced protein […]

Universität Heidelberg Successful with Application for Collaborative Research Centre

Universität Heidelberg Successful with Application for Collaborative Research Centre

DFG funds extended CRC with approximately 17.4 million euros Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG) with a grant application for a major research consortium: The Collaborative Research Centre “Molecular Circuits of Heart Disease” (CRC 1550), based at the Medical Faculty Heidelberg, is entering a second […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp